Greenyn Biotechnology Co

Greenyn Biotechnology Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Greenyn Biotechnology Co (6846.TWO) as of Nov 2, 2026 is -162.30 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 143.76 % — a change of -212.90% (lower).

FCF Conversion

-162.30 %

YoY

-212.90%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Greenyn Biotechnology Co is 2025 -162.30 % . FCF Conversion Rate (FCF/EBITDA) of Greenyn Biotechnology Co was 2024 143.76 % . It decreases by -212.90% lower compared to the previous year.

The Greenyn Biotechnology Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
118.07 TWD
Jan 1, 2020
202.17 TWD
Jan 1, 2021
48.24 TWD
Jan 1, 2022
144.88 TWD
Jan 1, 2023
28.88 TWD
Jan 1, 2024
143.76 TWD
Jan 1, 2025
-162.30 TWD
The Greenyn Biotechnology Co FCF Conversion history
YEARFCF ConversionYoY
-162.30 %-212.90%
143.76 %+397.84%
28.88 %-80.07%
144.88 %+200.32%
48.24 %-76.14%
202.17 %+71.23%
118.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Greenyn Biotechnology Co Stock analysis

What does Greenyn Biotechnology Co do? Greenyn Biotechnology Co., Ltd. generates revenue through the research, development, manufacture, and sales of health food raw materials across three business segments: health ingredients, health formulations, and other segments. Its main products include Antrodia cinnamomea mycelia, Bitter melon extract (Insumate), and 101 Phyto Fermented Drink, which are primarily sold in Taiwan and other Asian regions. The company focuses on supplying these health-focused products to customers within the Asian market, leveraging its product portfolio for regional demand. The firm's product lineup targets health-conscious consumers seeking natural health solutions, with Antrodia cinnamomea mycelia and Bitter melon extract (Insumate) serving as key offerings. 101 Phyto Fermented Drink represents another core product, emphasizing plant-based health benefits. These products are distributed through established channels in Taiwan and neighboring Asian markets, supporting the company's regional sales strategy. Greenyn Biotechnology's business model centers on developing and commercializing specialized health ingredients and formulations, with a strong emphasis on Asian market penetration. The company's revenue streams are derived from the direct sale of its proprietary health food raw materials to customers in Taiwan and other Asian regions, without mentioning external partners or additional distribution channels beyond the specified markets. Greenyn Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Greenyn Biotechnology Co stock

FCF Conversion Rate (FCF/EBITDA) of Greenyn Biotechnology Co is -162.30 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Greenyn Biotechnology Co changed from 143.76 % to -162.30 %, representing a -212.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Greenyn Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Greenyn Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Greenyn Biotechnology Co

All Key Metrics — Greenyn Biotechnology Co